Metabolic Therapy Prevents Childhood Stroke Disease in Genetic Mouse Model

This groundbreaking study reveals why children with specific ACTA2 gene mutations develop moyamoya disease - a devastating condition causing brain vessel blockages and childhood strokes. The research team discovered that smooth muscle cells carrying the R179C mutation fail to mature properly, maintaining stem cell-like characteristics including excessive migration and reliance on glycolysis rather than efficient mitochondrial energy production.

Using both cell culture and mouse models, researchers found that mutant smooth muscle cells had 2.5-fold higher glycolytic activity and significantly reduced oxidative phosphorylation compared to normal cells. These immature cells migrated excessively and accumulated inside blood vessels, creating the characteristic blockages seen in moyamoya disease.

The breakthrough came when researchers treated cells with nicotinamide riboside (NR), a vitamin B3 derivative that boosts mitochondrial function. NR treatment increased oxidative phosphorylation by 40% while reducing glycolysis, driving the mutant cells to differentiate into mature, less migratory smooth muscle cells. In mouse experiments, 22% of untreated mutant mice died after carotid artery injury, developing brain lesions and neuronal loss. However, NR pretreatment prevented all deaths and completely blocked vessel occlusions.

This research provides the first mechanistic explanation for moyamoya disease pathogenesis and demonstrates that metabolic interventions can prevent this devastating childhood condition. The findings suggest that targeting cellular metabolism could offer new therapeutic approaches for genetic vascular diseases, potentially preventing strokes in at-risk children before symptoms develop.